Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mabpharm Limited ( (HK:2181) ) has provided an announcement.
Mabpharm Limited has announced that its board of directors will convene on March 26, 2025, to review and approve the company’s annual financial results for the year ending December 31, 2024. This meeting is significant as it will address the company’s financial performance and any other business matters, potentially impacting its market positioning and stakeholder interests.
More about Mabpharm Limited
Mabpharm Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the development and commercialization of innovative drugs, primarily targeting the healthcare market.
YTD Price Performance: 96.43%
Average Trading Volume: 109,375
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$2.02B
For a thorough assessment of 2181 stock, go to TipRanks’ Stock Analysis page.